Waltham, MA — BostonGene announced that it has been named “Overall AI-based Analytics Company of the Year” in the ninth annual AI Breakthrough Awards program.
The awards program, conducted by AI Breakthrough, recognizes companies, technologies and products in the global artificial intelligence market. BostonGene was recognized for its multimodal AI infrastructure supporting oncology drug development.
BostonGene develops AI models for tumor and immune biology. The company’s integrated platform combines advanced AI models with CLIA/CAP-certified molecular profiling to convert complex tumor-immune biology into insights for clinical and drug development decisions.
The company said its platform embeds transcriptomic and immune system profiling into clinical workflows, helping biopharmaceutical companies model treatment response, resistance and safety. BostonGene said the approach is designed to support biomarker refinement, patient selection and portfolio prioritization across the drug development lifecycle.
“We are focused on addressing the most persistent, high-stakes challenges in oncology while anticipating and operationalizing key trends. The impact of our approach is reflected in outcomes like improved portfolio focus, reduced development risk, incorporation of immune-driven prediction into pre-treatment strategies to mitigate risk, and sharper patient stratification,” said Andrew Feinberg, President and CEO of BostonGene. “Thank you to AI Breakthrough for recognizing how we are redefining the way clinical and drug development decisions are made by shifting from exploratory analytics to actionable, decision-oriented intelligence.”
AI Breakthrough said this year’s program drew thousands of nominations from more than 20 countries across categories including Agentic AI, Generative AI, Computer Vision, AIOps, Robotics, Natural Language Processing and industry-specific AI applications.
“BostonGene delivers a robust, scalable approach to decision intelligence in oncology. Clinical programs experience high attrition rates, with most assets failing to reach the market. Imprecise patient stratification results in suboptimal outcomes and unnecessary toxicity, while development decisions made without sufficient biological filtering at the portfolio level stifle promising therapeutic paths,” said Steve Johansson, managing director, AI Breakthrough. “BostonGene is accelerating the delivery of life-saving therapies across the drug development lifecycle by enabling more informed development strategies, improved patient selection, and reduced uncertainty through AI.”
BostonGene said its platform is being used in collaborative programs with global pharmaceutical companies, including AstraZeneca, Johnson & Johnson, Daiichi Sankyo and Ottimo Pharma, as well as academic and clinical research networks.
